Features | Partner Sites | Information | LinkXpress
Sign In
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES
GLOBETECH PUBLISHING

Biomarker Improves Head and Neck Cancer Patient Prognosis

By Labmedica International staff writers
Posted on 31 Jan 2012
A molecular fingerprint in head and neck cancers can predict whether a patient's tumor will be life threatening.

The molecular fingerprint biomarker is considered particularly promising because it can detect the level of risk immediately following diagnosis. This biomarker could become a component of a new test to guide how aggressively those with head and neck tumors should be treated.

A study was performed at Albert Einstein College of Medicine of Yeshiva University (Bronx, NY, USA) and Montefiore Medical Center (Bronx, NY, USA), the University Hospital for Einstein. Tissue samples were taken from tumors and nearby healthy tissue of 123 head and neck cancer patients at Montefiore and levels of 736 microRNAs were measured. Of all the microRNAs measured, one in particular–miR-375– stood out for being the most down-regulated in head and neck tumors compared with its levels in adjacent normal tissue.

The 123 patients were ranked according to how extreme the difference was between the miR-375 in their tumor and in adjacent normal tissue, with that difference expressed as the ratio: miR-375 level in patient's tumor tissue divided by miR-375 level in patient's normal tissue. All patients were then followed throughout the course of their illness.

MiR-375 proved to be a highly useful biomarker for predicting disease outcome. The patients for whom the difference between their tumor and normal-tissue miR-375 levels was most extreme (i.e., the one-fourth of patients with the lowest ratios) were nearly 13 times more likely to die or 9 times more likely to experience distant spread (metastasis) of their cancer compared to patients with higher miR-375 ratios.

The findings were published online January 9, 2012, in the American Journal of Pathology.

Related Links:

Albert Einstein College of Medicine
Montefiore Medical Center


EUROIMMUN AG
Sekisui Diagnostics
PURITAN MEDICAL
comments powered by Disqus
Life Technologies

Channels

Clinical Chemistry

view channel
Image: Enzyme-linked immunosorbent kit (ELISA) specific for human copeptin (Photo courtesy of USCN Life Science).

Preeclampsia Biomarker Detected Very Early In Pregnancy

A biomarker has been discovered that could give expecting mothers and their doctors the first simple blood test to reliably predict that a pregnant woman may develop preeclampsia, at least as early as... Read more

Pathology

view channel
Image: Glioblastoma multiforme (GBM) (Photo courtesy of the University of California, San Diego School of Medicine).

Brain Tumor Chemotherapy Biomarkers Identified

Cancer researchers have identified a new biomarker that they believe can predict whether glioblastoma multiformes (GBMs), the most common and aggressive type of malignant brain tumor, will be susceptible... Read more

Lab Tech.

view channel
Image: The ADVIA Centaur XPT Immunoassay System delivers the results that clinicians depend upon for accurate diagnoses and better patient care (Photo courtesy of Siemens Healthcare).

Introduction of New Central Laboratory Clinical Analyzers Highlights Recent Lab Equipment Exposition

An impressive array of new automated analyzers for central diagnostic laboratories was unveiled at a recent lab equipment trade fair. The IFCC WorldLab exposition held June 22-26, 2014, in Istanbul... Read more

Industry News

view channel

EKF Wins Distribution Contract and Regulatory Approval for Target Regions

EKF Diagnostics Holdings (Cardiff, Wales, UK), an AIM-listed point-of-care, central laboratory and molecular diagnostics business, announced that it has signed a new distribution contract in China and that one of its OEM (original equipment manufacturer) partners has received further regulatory approval across several target... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.